Virtus Advisers LLC Purchases New Shares in Veracyte, Inc. $VCYT
Virtus Advisers LLC has acquired a new position in Veracyte, Inc. (NASDAQ:VCYT), purchasing 37,574 shares valued at approximately $2.2 million. Other institutional investors like BlackRock and First Trust Advisors also increased their holdings. This comes as Veracyte reported strong quarterly earnings, beating estimates with $0.54 EPS and 15.5% year-over-year revenue growth, despite some insider selling activities.
Lisanti Capital Growth LLC Purchases Shares of 63,400 Veracyte, Inc. $VCYT
Lisanti Capital Growth LLC has acquired 63,400 shares of Veracyte, Inc. (NASDAQ:VCYT) during the second quarter, valued at approximately $3.7 million. This purchase represents about 0.08% of the company's stock. The biotechnology company recently reported strong quarterly earnings, beating analyst estimates with $0.54 per share and a 15.5% year-over-year revenue increase to $150.32 million, leading to a "Moderate Buy" rating from analysts with an average price target of $54.33 despite recent insider stock sales.
Summit Creek Advisors LLC Takes Position in Veracyte, Inc. $VCYT
Summit Creek Advisors LLC has acquired a new position in Veracyte, Inc. (NASDAQ: VCYT), purchasing 118,956 shares valued at approximately $6.99 million, representing 2.4% of its portfolio. This comes as Veracyte exceeded quarterly earnings expectations, reporting $0.54 adjusted EPS against an estimate of $0.41, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $54.33. Insider selling occurred to cover tax obligations, while the stock currently trades around $40.68.
Top 3 Health Care Stocks That Could Blast Off This Month
This article identifies three oversold health care stocks—Veracyte Inc (VCYT), Akso Health Group (AHG), and Inogen Inc (INGN)—that could present buying opportunities this month. Using the Relative Strength Index (RSI) as an indicator, these companies are highlighted for having an RSI near or below 30, suggesting they may be undervalued. Recent company news and price actions are provided for each stock.
Veracyte Inc (VCYT) News, Articles, Events & Latest Updates
This article compiles recent news and updates regarding Veracyte Inc (VCYT), including analyst ratings, earnings reports, and stock performance. It highlights that VCYT is technically oversold, has surpassed Q2 earnings estimates, and has crossed its average analyst target price, suggesting potential for a trend reversal.
Rice Hall James & Associates LLC Invests $5.61 Million in Veracyte, Inc. $VCYT
Rice Hall James & Associates LLC has acquired a new stake in Veracyte, Inc. (NASDAQ:VCYT) worth approximately $5.61 million, representing 0.12% of the biotechnology company. Veracyte surpassed quarterly earnings and revenue estimates, and analysts generally maintain a "Moderate Buy" rating with an average price target of $54.33. Insider selling was noted, primarily to cover tax obligations related to equity awards.
Is Veracyte (VCYT) Undervalued As Raised 2026 Outlook And Q2 Earnings Lift Interest?
Veracyte (VCYT) is attracting investor attention after raising its 2026 revenue outlook and reporting a shift from net loss to net income in Q2, driven by new cancer diagnostics. Despite a recent share price pullback, its longer-term performance remains strong, with a 90-day return of 40% and a one-year return of 95.9%. The article discusses whether the current dip presents a buying opportunity, noting Veracyte is considered 18.1% undervalued based on its pipeline and earnings profile, but also highlights valuation risks due to its P/E ratio being higher than industry averages.
Veracyte Inc (VCYT) Shares Fall 3.2% -- GF Value Says Still Overvalued
Veracyte Inc (VCYT) shares dropped 3.2% to $41.25, placing it 6.7% overvalued compared to its GF Value™ of $38.65, despite a strong GF Score™ of 80/100. Insider selling totaling $9.7 million over the past three months, with no reported buying, suggests caution for potential investors. The company's P/E ratio of 29.3x is significantly below its 5-year median, indicating a lower current valuation relative to its historical performance.
Veracyte Debuts Prosigna Breast Test in the U.S.
Veracyte Inc. has launched its Prosigna Breast Risk of Recurrence (ROR) test in the U.S. This genomic assay helps patients with early-stage hormone-receptor positive breast cancer determine their 10-year risk of distant recurrence, guiding personalized treatment decisions, including whether chemotherapy will be beneficial. The Prosigna test uniquely combines intrinsic subtypes, proliferation score, and clinical factors to offer comprehensive and prognostically accurate insights, particularly for high-risk populations.
Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT
Bank of America Corp DE increased its stake in Veracyte, Inc. by 14.7% in the first quarter, holding 1.45 million shares valued at $46.7 million. Other institutional investors also raised their positions, and analysts maintain a "Moderate Buy" rating with an average target price of $54.33. Veracyte surpassed Q1 earnings and revenue expectations, though insiders sold a significant amount of stock, mainly through planned transactions.
How Investors May Respond To Veracyte (VCYT) Raising 2026 Revenue Guidance After Returning To Profit
Veracyte (VCYT) has raised its full-year 2026 revenue guidance to $590-$596 million and reported a return to profit in Q2 2026, with net income of $25.49 million. This improved outlook, driven by increasing test adoption, strengthens the company's investment narrative, although risks around reimbursement pressure and product concentration remain. Analysts project $744.2 million revenue and $115.6 million earnings by 2029, suggesting a fair value of $56.55 per share, a 22% upside.
A Look at Veracyte Inc (VCYT) After 3.7% Decline -- GF Value $38
Veracyte Inc (VCYT) shares recently declined by 3.7%, trading at $44.68, which is 15.6% above its GF Value™ estimate of $38.64, indicating it is "modestly overvalued." Despite a strong GF Score™ of 82/100, driven by high growth and financial strength, the company has a lower profitability rank and experienced significant insider selling totaling $9.7M. This suggests investors should exercise caution due to the overvaluation and potential divergence in insider sentiment.
Amundi Sells 116,588 Shares of Veracyte, Inc. $VCYT
Amundi significantly reduced its stake in Veracyte, Inc. by selling 116,588 shares, a 90.6% decrease, though other institutional investors increased their holdings. Veracyte surpassed Q1 earnings and revenue estimates, reporting $0.54 EPS and $150.32 million in revenue, leading analysts to maintain a "Moderate Buy" rating with an average price target of $54.33. Insider trading activity showed sales by a director and chief accounting officer totaling over $1.2 million.
Veracyte at canaccord growth conference: growth balanced with margins
Veracyte (VCYT) outlined a strategy for growth balanced with disciplined spending at Canaccord Genuity’s 46th Annual Growth Conference. The company raised its full-year 2024 revenue guidance to $600 million after strong Q2 results, achieving over 29% adjusted EBITDA margin and over $40 million in cash generation. While Decipher volume growth slowed due to a guideline change affecting low-risk segments, Afirma continued to benefit from a sequencer transition, and new products Prosigna and TrueMRD were launched, though not yet materially contributing to revenue.
Veracyte, Inc. $VCYT Shares Sold by Janus Henderson Group PLC
Janus Henderson Group PLC reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 31% in the first quarter, selling 84,255 shares but still retaining 187,368 shares valued at approximately $6 million. Despite this sale, analyst sentiment remains largely positive with a "Moderate Buy" rating and an average price target of $54.33. Other institutional investors like Jane Street and UBS Asset Management increased their positions in Veracyte, while the company reported strong quarterly earnings of $0.54 per share, beating estimates.
Royal Bank of Canada Grows Stock Holdings in Veracyte, Inc. $VCYT
Royal Bank of Canada increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 66.4% in the first quarter, acquiring an additional 228,720 shares, bringing its total to 573,096 shares valued at approximately $18.46 million. This move is part of a broader trend of institutional investors boosting their positions in Veracyte, while company insiders have sold shares worth about $9.68 million over the past 90 days. Veracyte also reported strong quarterly earnings, beating analyst expectations with $0.54 EPS and $150.32 million in revenue, a 15.5% year-over-year increase, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $54.33.
Veracyte Inc (VCYT) Earnings Forecast: Future EPS & Revenue Growth Estimates
Veracyte Inc (VCYT) has an earnings forecast score of 8.46, ranking 126th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $48.00, with a consensus "Buy" rating based on 13 analysts. The company's expected revenue for the next quarter is $147.64 million, and its previous quarter's EPS was $0.36, exceeding the market expectation of $0.32.
Results: Veracyte, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Veracyte, Inc. exceeded analyst expectations for its quarterly results, with revenues hitting US$150m and statutory EPS at US$0.31, 19% above forecasts. Following these positive results, analysts have slightly increased their earnings per share outlook for 2026, though the consensus revenue estimates remain largely unchanged. Despite the improved earnings potential, the consensus price target for Veracyte held steady at US$57.82, and the company's projected revenue growth is expected to be slower than the wider industry.
Results: Veracyte, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Veracyte, Inc. exceeded analyst expectations for its recent quarterly results, with revenues reaching US$150 million and statutory EPS at US$0.31, both higher than forecasts. Following these positive results, analysts have modestly increased their revenue and earnings per share predictions for 2026, though the consensus price target remains unchanged at US$57.82. The company's revenue growth is expected to slow compared to historical rates and the wider industry.
Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests
Veracyte, Inc. (VCYT) reported strong Q2 2026 results, with revenue up to US$150.32 million and a net income of US$25.49 million, prompting an increase in its full-year 2026 revenue guidance to US$590 million to US$596 million. This positive outlook is attributed to the successful launch of new cancer tests, Prosigna and TrueMRD, which are expanding the company's presence in cancer diagnostics. While the new tests reinforce Veracyte's growth story, the company still faces risks related to sustained clinical adoption, payer coverage, and potential over-reliance on a few flagship tests.
VERACYTE INC : PIPER SANDLER CUTS TARGET PRICE TO $54.00 FROM $66.00
Piper Sandler has reduced its target price for VERACYTE INC (VCYT.O) to $54.00 from $66.00. This report was issued by Reuters on August 4, 2026. The article advises readers that its content reflects the author's opinion and should not be used as the sole reference for investment decisions.
Medicare Coverage Granted for Veracyte’s Test for Muscle-Invasive Bladder Cancer
Veracyte Inc.'s TrueMRD Monitoring Test has received Medicare coverage for recurrence monitoring in patients with muscle-invasive bladder cancer (MIBC) following definitive treatment. This marks Veracyte's first molecular residual disease (MRD) offering and the only commercially available whole-genome MRD test, significantly expanding its reach into cancer recurrence monitoring. The test can detect recurrence earlier than imaging, offering a powerful new tool for clinicians to make more informed treatment decisions.
VCYT Maintained by Stephens & Co. -- Price Target Lowered to $55
Stephens & Co. has maintained an Overweight rating for Veracyte (VCYT) but lowered its price target from $68.00 to $55.00. The stock is currently considered 16.3% overvalued by GuruFocus, trading at $44.84 against a GF Value™ of $38.56, despite a strong GF Score™ of 78/100, which highlights its financial strength and growth potential. Insider selling of $10.1 million over the past three months suggests potential concerns from within the company.
VERACYTE INC : PIPER SANDLER CUTS TARGET PRICE TO $54.00 FROM $66.00
Piper Sandler has cut its target price for Veracyte Inc. (VCYT.O) from $66.00 to $54.00. This adjustment reflects a revised outlook from the analyst firm regarding the company's financial prospects.
Canaccord cuts Veracyte stock price target to $50 on revenue outlook
Canaccord Genuity lowered its price target on Veracyte (NASDAQ:VCYT) to $50 from $60, while maintaining a Hold rating, due to reduced revenue estimates in its long-term DCF model. Despite an impressive second quarter and raised 2026 revenue guidance, Veracyte's stock is considered overvalued by InvestingPro. Other analysts, Freedom Capital and Needham, raised their price targets and maintained Buy ratings following strong Q2 results.
Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests
Veracyte (VCYT) shares dropped 18.2% despite the company raising its full-year 2026 revenue guidance to US$590 million to US$596 million, up from a previous range, following strong Q2 results of US$150.32 million revenue and US$25.49 million net income. This improved outlook is attributed to the launch of new cancer tests, Prosigna and TrueMRD, which are starting to contribute to growth, though the company still faces risks related to clinical adoption and payer coverage for new tests. Analysts project Veracyte's revenue to reach $744.2 million and earnings to hit $115.6 million by 2029, suggesting a fair value of $56.55 with a 22% upside.
Canaccord cuts Veracyte stock price target to $50 on revenue outlook
Canaccord has lowered its price target for Veracyte (NASDAQ: VCYT) to $50 from $60, while maintaining a Hold rating due to reduced revenue estimates in future years of its DCF model. Despite beating Q2 2026 estimates and increasing 2026 revenue guidance, Veracyte's stock dropped 16.7% over the past week and Canaccord remains on the sidelines awaiting significant adoption of newly launched tests. Other analysts, Freedom Capital and Needham, recently raised their price targets for Veracyte following its strong Q2 performance.
VERACYTE, INC. 2026: Revenue $150.32M, EPS $0.31— 10-Q Summary
Veracyte (VCYT) reported its second-quarter 2026 results, showing significant growth with revenue reaching $150.32M and diluted EPS of $0.31. This represents a 15.5% year-over-year increase in revenue and a substantial turnaround from a net loss in the previous year, driven by strong testing revenue and operational scaling. The company also increased R&D spending to advance new products and clinical studies.
Needham raises Veracyte stock price target to $69 on strong Q2 beat
Needham has increased its price target for Veracyte (NASDAQ:VCYT) shares to $69 from $57, maintaining a Buy rating, following the company's strong second-quarter results where revenue and EPS surpassed consensus estimates. Veracyte also raised its 2026 revenue guidance and is noted for its financial health, including no debt and profitability. Despite a post-earnings stock decline, the company's performance highlights its exceeding financial expectations and ongoing initiatives for growth.
Veracyte, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:VCYT) 2026-07-31
Veracyte, Inc. (VCYT) published a slide deck for its 2026 Q2 earnings call, reporting earnings per share (EPS) of $0.54, which beat estimates by $0.11. The company's revenue reached $150.32 million, surpassing expectations by $5.84 million and representing a 15.49% year-over-year increase. This presentation provides detailed insights into their financial performance for the second quarter of 2026.
Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates
Veracyte (VCYT) reported strong Q2 results, with earnings of $0.54 per share and revenues of $150.32 million, both surpassing Zacks Consensus Estimates. The company has consistently exceeded EPS and revenue expectations over the past four quarters, and its stock has significantly outperformed the S&P 500 year-to-date. Despite the positive performance, Veracyte currently holds a Zacks Rank #4 (Sell) due to unfavorable earnings estimate revisions.
Transcript : Veracyte, Inc., Q2 2026 Earnings Call, Jul 30, 2026
This article is a transcript of Veracyte, Inc.'s Q2 2026 Earnings Call held on July 30, 2026. The company reported increased Q2 non-GAAP earnings and revenue, leading to a raised revenue guidance for the full year 2026. The transcript includes opening remarks and indicates that the full content is reserved for subscribers.
Veracyte posts 15% revenue surge in Q2, raises FY26 guidance
Veracyte Inc. reported a strong Q2 2026 with a 15% revenue increase, reaching $150.3 million, and a significant turnaround to a GAAP net income of $25.5 million. Driven by robust demand for its cancer diagnostics portfolio, particularly Decipher Prostate and Afirma tests, the company raised its full-year 2026 sales guidance to $590-$596 million. Veracyte also launched new products, the Prosigna Breast Test and TrueMRD Monitoring Test, with the latter securing Medicare coverage, positioning the company for continued double-digit growth.
Veracyte Releases Q2 2026 Financial Results
Veracyte (NASDAQ: VCYT) reported strong Q2 2026 financial results, with non-GAAP EPS of $0.54, surpassing estimates, and revenue of $150.3M, exceeding expectations by 4.0%. The company's Decipher Prostate test was a key growth driver, and full-year revenue guidance is set at $590.0M to $596.0M. These results demonstrate Veracyte's continued expansion in genomic diagnostics.
Earnings Flash (VCYT) Veracyte, Inc. Posts Q2 Adjusted EPS $0.54 per Share, Vs. FactSet Est of $0.43
Veracyte, Inc. (VCYT) reported its Q2 adjusted EPS of $0.54 per share, significantly surpassing the FactSet estimate of $0.43 per share. This financial update highlights the company's strong performance during the second quarter.
Veracyte: Q2 Earnings Snapshot
Veracyte Inc. (VCYT) reported robust second-quarter results, with profits reaching $25.5 million, or 31 cents per share. After adjustments, earnings were 54 cents per share, surpassing Wall Street's expectation of 43 cents. The molecular diagnostic company also exceeded revenue forecasts, posting $150.3 million against an expected $144.4 million, and anticipates full-year revenue between $590 million and $596 million.
Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat
Veracyte, Inc. (VCYT) saw its shares advance significantly during Q2 2026 due to a strong earnings beat and raised full-year guidance, driven by double-digit volume growth in its Decipher test and improved Afirma performance. Meridian Small Cap Growth Fund highlighted VCYT as a key contributor to its performance, noting the company's profitable genomic diagnostics business and upcoming product launches. Despite its potential, Veracyte was not among the 40 most popular stocks among hedge funds heading into 2026, though 32 hedge funds held positions in Q1 2026.
VCYT|Veracyte Inc|Price:55.730|Chg%:+0.080
This article provides a comprehensive analysis of Veracyte Inc (VCYT), highlighting its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It details the company's diagnostic products for various cancers, institutional ownership, and analyst ratings, indicating a positive medium-term outlook despite recent sideways stock price movement. The report also explains TradingKey's methodology for generating stock scores across several critical dimensions.
Veracyte, Inc. Revenue Breakdown – TRADEGATE:12V
Veracyte, Inc. generated €440.31 million in revenue last year, primarily from its Diagnostic Tests and Biopharmaceutical Services segment. The United States was the leading contributor to this revenue, accounting for €422.81 million. This shows an increase in both total revenue and U.S. contributions compared to the previous year.
Veracyte Inc (VCYT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Veracyte Inc (VCYT), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests VCYT is suitable for range-bound swing trading, with indicators showing mixed signals (Sell, Neutral, Buy) across different timeframes. Overall, based on moving averages and other technical indicators, the signal for Veracyte Inc is currently Neutral.
Veracyte to present at two major healthcare investor conferences in August and September 2026
Veracyte, a cancer diagnostics company, announced its participation in two key healthcare investor conferences: the Canaccord Genuity Growth Conference in August and the Morgan Stanley Global Healthcare Conference in September 2026. The company will conduct fireside chats at both events to discuss its diagnostic platform and cancer care innovations. Live and archived webcasts of these presentations will be available on Veracyte's website, providing investors insights into the company's latest developments in molecular cancer diagnostics.
Veracyte to offer live audio webcasts for two investor chats
Veracyte (Nasdaq: VCYT) announced its participation in two upcoming investor conferences: the Canaccord Genuity 46th Annual Growth Conference on August 11, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. The company will host live audio webcasts and 90-day replays of its fireside chats for both events on its investor relations website. Veracyte is a cancer diagnostics company focused on transforming cancer care through molecular tests and its advanced Diagnostics Platform.
Veracyte, Inc. Revenue Breakdown – NASDAQ:VCYT
Veracyte, Inc. (VCYT) generated $517.14 million in revenue last year, primarily from its Diagnostic Tests and Biopharmaceutical Services segment. This represents an increase from $445.76 million in the previous year. The United States was the dominant contributor to this revenue, accounting for $496.60 million.
Veracyte to Participate in Upcoming Investor Conferences
Veracyte, Inc. announced its participation in two upcoming investor conferences: the Canaccord Genuity 46th Annual Growth Conference on August 11th, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15th. The company, a leading cancer diagnostics firm, will host fireside chats at both events. Live audio webcasts and replays of these presentations will be available on Veracyte's investor relations website.
VCYT|Veracyte Inc|Price:55.615|Chg%:-0.995
Veracyte Inc (VCYT) stock is trading at $55.65, up 0.07% as of July 28, 2026. The company has a market cap of $4.44 billion and a P/E TTM of 49.91. Analysts currently rate VCYT as a "Buy" with a target price of $57.83, suggesting a 2.16% upside.
Veracyte Inc (VCYT) Institutional Confidence
Veracyte Inc's institutional shareholding score is 10.00, placing it first in the Biotechnology & Medical Research industry. The company's institutional shareholding proportion increased by 6.15% quarter-over-quarter to 120.44%. Catherine Wood is the largest institutional shareholder, holding 2.21 million shares, representing 3.83% of outstanding shares.
Veracyte Inc (VCYT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Veracyte Inc (VCYT)'s dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock performance data for VCYT, including its market cap and P/E ratio.
VCYT|Veracyte Inc|Price:56.610|Chg%:-1.270
This article provides a detailed financial overview of Veracyte Inc. (VCYT), including its stock performance, market capitalization, P/E ratio, and upcoming earnings information. It presents comprehensive quarterly and annual financial data, such as EPS, revenue, net profit, margins, and balance sheet items, allowing investors to analyze the company's market health. The report also includes an FAQ section addressing key financial figures from the FY2025 earnings report.
Veracyte Inc (VCYT) Earnings Forecast: Future EPS & Revenue Growth Estimates
Veracyte Inc (VCYT) has an earnings forecast score of 8.50, ranking 106th in the Biotechnology & Medical Research industry. Analysts project an average price target of $48.00, with a high of $57.00 and a low of $43.00, and a "Buy" trend recommendation from 13 analysts. The company's expected revenue for the next quarter is $144.55 million, and its EPS for the previous quarter was $0.52, while the next quarter's EPS is estimated at $0.24.
Veracyte Inc (VCYT) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Veracyte Inc (VCYT), indicating its current score is 7.18 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of 49.88, noting its relation to recent highs and lows. While the P/E ratio is given, other key metrics like P/B, P/S, and P/CF are reported as not yet disclosed by the company.
